There are remarkably few reasons not to take emtricitabine. The restrictions that exist concern combinations and kidney function rather than any inherent problem with the drug.
Who should not take it?
Anyone already taking lamivudine, since the two work identically and offer no benefit together. Anyone with a documented hypersensitivity to it, which is uncommon. Beyond that, the list is short.
What about kidney impairment?
Not a prohibition but a dosing question. Emtricitabine is cleared by the kidneys and the dosing interval is extended where function is reduced. Because fixed-dose combination tablets cannot be adjusted, someone with significantly reduced function is usually switched to a different product.
What about hepatitis B?
Not a reason to avoid it. What it means is that stopping cannot be casual, because emtricitabine suppresses hepatitis B and abrupt withdrawal can cause a liver flare. Where hepatitis B needs treating properly, a tenofovir-containing regimen is preferred, since emtricitabine alone is not adequate for it.
What if you have the M184V mutation?
This is the single mutation that confers resistance to emtricitabine and lamivudine. Its presence does not automatically rule out using them, since it also weakens the virus and increases susceptibility to some other drugs, and regimens are sometimes designed to retain it deliberately. That is a specialist decision based on your full resistance profile.
What about pregnancy?
Widely used in pregnancy, in both treatment and prevention, with one of the longer safety records among antiretrovirals. Nobody should stop it because of a pregnancy without a clinical conversation, since untreated HIV carries far greater risk than the medication.
What about children?
Used from infancy, with weight-based dosing and an oral solution available. Paediatric prescribing follows specific guidance.
What about older people?
No particular restriction, though kidney function declines naturally with age and is monitored accordingly. Where function has fallen enough to matter, the answer is usually a change of product rather than avoidance of this component.
What is the closest alternative?
Lamivudine, which is essentially interchangeable in most treatment regimens and appears in several combinations including with dolutegravir and with abacavir. If you cannot have one, the other is generally available.
What alternatives avoid both?
Some two-drug regimens use neither, such as dolutegravir with rilpivirine, or long-acting cabotegravir with rilpivirine. These are options for people already suppressed rather than for everyone, and suitability depends on resistance history.
What are the alternatives for prevention?
Injectable cabotegravir, given every two months, and lenacapavir, given twice yearly where available. Both remove daily dosing entirely and require reliable attendance and testing before each injection.
What about prevention without medication?
Condoms remain fully effective, and a partner with a sustained undetectable viral load cannot transmit HIV sexually. Neither requires anything daily, and the best prevention method is the one you will actually keep using.
How would you know if you were taking both?
By reading the components of every tablet you take rather than the brand name. Emtricitabine and lamivudine appear in many products under different names, and the overlap usually happens when a new regimen is added without the old one being fully reviewed.
What should you tell your clinic?
Everything you take, including anything prescribed elsewhere. This is the single interaction that matters with emtricitabine, and it is entirely avoidable with a complete list.
Is stopping it ever straightforward?
For PrEP, yes, with the two or seven day tail depending on the kind of sex. For treatment, never independently, and with chronic hepatitis B never without a plan, since a flare of liver inflammation is a real risk.
What if it is the only option available?
Rarely the case. HIV medicine now has enough options that almost every situation has an alternative, and where choices genuinely are limited a specialist will construct something around your resistance profile. Being told there is nothing else is worth a second opinion.
Who decides?
You do, with a clinician. Suitability is a clinical judgement and the choice between suitable options is yours, including on grounds like convenience, appearance of tablets or how a schedule fits your life. Those are legitimate reasons rather than trivial ones.